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Abstract 
The present study was designed to examine the development of structural changes, characteristic of diabetic 
neuropathy, in chronic galactosemia and their responsiveness to inhibition of the polyol-pathway. Sprague-Dawley 
rats weighing 70-90 g were given a 50% galactose diet continued for 4 or 8 months. Half of these animals were 
simultaneously given the aldose reductase inhibitor (ARI) WAY 121-509. ARI-treatment normalized galactitol and 
myoinositol levels in the sciatic nerve. At 4 months, sciatic nerve conduction velocity (NCV) in galactosemic rats was 
reduced by 30% which was prevented in ARI-treated rats. At 8 months galactosemia reduced NCV to 58% of control 
values, while ARI-treatment for 8 months improved NCV to 71% of control values. ARI-treatment prevented in galac- 
tosemic rats nodal structural changes characteristic of diabetic neuropathy, whereas axonal atrophy was not affected 
by ARI-treatment, which may in part account for the only partial prevention of the NCV slowing at 8 months. Nerve 
fiber regeneration was increased 4-fold in ARI-treated rats compared with untreated galactosemic rats. These data sug- 
gest that chronic galactosemia produces a neuropathy structurally similar to diabetic neuropathy. The lack of an ARI- 
treatment effect on axonal atrophy suggests that this defect is not polyol related in galactosemia. 
Keywords: Galactosemia; Axo-glial dysjunction; ARI-treatment; Regeneration 
1. Introduction 
Activation of the polyol-pathway has emerged 
as an important metabolic abnormality, believed 
to underlie chronic diabetic complications, in par- 
titular diabetic polyneuropathy [ 1,2]. Increased 
* Corresponding author. 
polyol-pathway flux causes a reciprocal depletion 
of peripheral nerve myoinositol [3] affecting 
phosphoinositide turnover which in turn results in 
reduced Nat/K+-ATPase activity via a decreased 
release of diacylglycerol [4]. In order to separate 
the polyol-pathway related metabolic effects on 
peripheral nerve in diabetes from the potential ef- 
fects caused by other effects of hyperglycemia or 
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insulin deficiency, chronic galactosemia in rodents 
has emerged as a valuable experimental model 
[5-81. The rationale for such models lies in the fact 
that galactosemia activates the polyol-pathway in 
a fashion similar to hyperglycemia. Galactose is 
transformed into galactitol by aldose reductase, 
but unlike sorbitol generated by glucose, is not 
further metabolized [9]. 
Although the galactosemic models show several 
similarities with diabetic neuropathy, such as slow- 
ing of nerve conduction velocity (NCV), decreased 
peripheral nerve blood flow, and axonal atrophy 
and degeneration [5-8, lo- 121, distinct dissimilar- 
ities also exist. Despite the fact that activation of 
the polyol-pathway by galactosemia leads to 
peripheral nerve myo-inositol depletion, Na+/K+- 
ATPase activity is increased in galactosemic 
neuropathy [7,13] rather than decreased as is 
characteristic of diabetic neuropathy. With respect 
to the structural responses, chronic galactosemia is 
associated by marked endoneurial edema, myelin 
bubbling, de- and re-myelination [5], which are 
not prominent features of diabetic neuropathy 
114-161. Common to both neuropathies is the 
slowing of NCV, which in both diabetic and galac- 
tosemic neuropathy is prevented by the treatment 
with aldose reductase inhibitors (ARIs) [7,17]. 
Since the functional and structural integrity of 
the node of Ranvier is paramount to normal nerve 
impulse transmission 118-221, it is surprising that 
this anatomic site has received no attention in 
galactosemic neuropathy. This is even more sur- 
prising, since a series of structural and causally 
interrelated functional abnormalities of the nodal 
apparatus has been described in both experimental 
and human diabetic neuropathy, abnormalities 
which are ameliorated by ARI-treatment [15, 
22-261. 
In the present study the effects of chronic galac- 
tose feeding and their responses to ARI-treatment 
were examined in peripheral rat nerve with partic- 
ular emphasis on the pathology of the node of 
Ranvier. 
2. Material and methods 
2.1. Animals 
Thirty Sprague-Dawley rats were used in this 
study. Twenty rats weighing 70-90 g were started 
on a 50% galactose-diet (Bioserve, Springfield, 
NY) which was continued for 4 or 8 months. Con- 
trol rats were given a standard synthetic rat chow 
(ICN Biomechanicals, Cleveland, OH). Simul- 
taneously with the initiation of the galactose diet, 
10 rats were given the AR1 WAY 121-509 (Wyeth- 
Ayerst Research, Princeton, NJ) admixed to the 
diet at concentrations providing a daily dose of 25 
mg/kg body wt. Groups of 5 rats consisting of age- 
and sex-matched control rats, galactose-fed, and 
AR&treated galactosemic rats were killed at 4 
months and 8 months of the study protocol. All 
animals were allowed free access to diet and water, 
and were exposed to a 12-h light-dark cycle. 
2.2. Nerve conduction velocity (NCV) 
On the day before killing the rats, NCV was 
measured in the sciatic-tibia1 conducting motor- 
system under temperature controlled (35-37”(Z) 
conditions as previously described 1231. In brief, 
animals were lightly anesthetized with halothane 
(Wyeth-Ayerst, Philadelphia, PA). NCV was 
determined non-invasively. The left sciatic nerve 
was stimulated at the sciatic notch and the tibia1 
nerve at the ankle by supramaximal(8 V) stimulat- 
ing pulses using a Cadwell 5200A electromyograph 
(Cadwell Laboratory Inc., Kennewick, WA). The 
compound-evoked motor responses were recorded 
from the first interosseous muscle. NCV, express- 
ed as m/s, was calculated by subtracting the distal 
from the proximal latency (measured in ms) divid- 
ed into the distance (measured in mm) between the 
two stimulating electrodes. 
2.3. Tissue collection 
Non-fasted animals were anesthetized with 
halothane. The left sciatic nerve was dissected, 
weighed and rapidly frozen in dishes cooled with 
dry ice. The animals were then subjected to full 
body perfusion with approximately 500 ml of 2.5% 
glutaraldehyde buffered with 0.1 M cacodylate- 
buffer (pH 7.40) at a pressure of 150 mmHg. The 
right sural nerve was carefully dissected and im- 
mersed in the same fixative for 2 h at 4”C, and 
post-fixed in cacodylate-buffered (0.1 M) 1% 
osmium tetroxide (pH 7.40) for 2 h at 4°C. The 
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distal portion of the sural nerve was dehydrated in 
an ascending series of ethanol and embedded in 
Epon. The proximal portion was dehydrated and 
used for systematic random teasing of myelinated 
fibers in unpolymerized Epon as previously 
described [23]. 
2.4. Biochemical Analyses 
Tissue galactose, galactitol, glycose, sorbitol, 
fructose, and myoinositol levels were quantitated 
using a gas chromatographic procedure according 
to the method described by Guerrant and Moss 
[27]. This procedure involves conversion of 
aldoses to their corresponding aldonitrile acetates 
and polyols to their corresponding acetates. These 
derivatives were separated and quantitated with a 
Hewlett Packard gas chromatograph (Model 5890; 
Piscataway, NJ), equipped with a capillary column 
with a cross-linked methyl silicone phase and a 
flame ionization detector. This procedure results 
in a linear instrument response for polyol concen- 
trations ranging from 0.5 to 300 pg and has a limit 
of detection of 0.04 nmol/mg tissue. Values were 
expressed as nmol/mg wet weight of tissue. 
2.5. Morphometric and morphological analyses 
Semi-thin (0.75 pm) cross sections of the sural 
nerve were stained with paraphenylene diamine for 
light microscopic morphometric analysis using a 
computerized Image-l image analysis system (Uni- 
versal Imaging Corp., West Chester, PA) equipped 
with a Hamamatsu high resolution CCD camera 
attached to a Nikon Optiphot 2 microscope 
(Mager Scientific, Dexter, MI) equipped with a 
Ludl automatic stage (Fryer Company, Huntley, 
IL). The data were compiled using an 80486 PC 
with 8 Mb of RAM. This system allows for assess- 
ment of the total complement of sural nerve 
myelinated fibers and provides the following 
measures: mean myelinated fiber size (pm2), 
myelinated fiber density (nlmm2), coefficient of 
variation of fiber densities (CV) between image- 
frames, and myelinated fiber occupancy (percen- 
tage of endoneurial area occupied by myelinated 
fibers) and axon/myelin ratio. Ultrathin longitudi- 
nal sections were examined in g-month animals 
with respect to the ultrastructural integrity of the 
paranodal ion-channel barrier, which is made up 
by a series of junctional complexes (axoglial junc- 
tions) attaching the terminal Schwann cell loops to 
the paranodal axolemma [8,23]. Abnormality of 
this barrier was expressed as percentage of axo- 
glial dysjunction, as previously described [23]. 
Ultrathin cross sections of the sural nerve were 
examined electron-microscopically for qualitative 
changes. 
2.4. Teased fiber evaluation 
A mean of 198 f 10 myelinated fibers were 
teased from each sural nerve of 8-month animals. 
They were scored as to the presence of the follow- 
ing structural changes; normality, paranodal swel- 
ling, paranodal demyelination, excessive myelin 
wrinkling, intercalated nodes, Wallerian degenera- 
tion, segmental degeneration, and remyelina- 
tion/regeneration, as previously defined in detail 
VI. 
2.7. Statistical evaluation 
All data are expressed as mean f S.E.M., 
unless otherwise stated. Significance of differences 
was calculated by analysis of variance (ANOVA), 
and Scheffe’s test. All measurements were per- 
formed by investigators who were unaware of the 
identity of the tissues. 
3. Results 
3.1. Body weights 
Four months of galactosemia resulted in a 33% 
reduction in body weight which was not signifi- 
cantly affected by ARI-treatment. At 8 months of 
galactosemia there was a 40% reduction in body 
weight, which showed a significant (P < 0.05) 16% 
prevention following ARI-treatment (Table 1). 
3.2. Nerve conduction velocity 
Galactosemia of 4 months duration resulted in 
a 30% (P C 0.0001) reduction in NCV, which was 
completely prevented by ARI-treatment (Table 1). 
Eight months of galactosemia was accompanied 
by a 48% (P < 0.0001) reduction in NCV which 
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The effect of galactosemia and ARI-treatment on body weight gain and motor nerve conduction velocity at 4 and 8 months 
Body weight (g) Motor nerve condution velocity (m/s) 
4 months 8 months 4 months 8 months 
(n = 5) (n = 5) (n = 5) (n = 5) 
Control 294 4 f 8.8”-b 
198:l zt 7.5”~’ 
364.8 f 18.2 51.1 f 3.5e.f 62.0 f 0.3sh 
Galactose 218.2 f 7.7cJ 35.6 f 0.9e.k, 36.2 f 0.54s.’ 
Galactose + AR1 208.6 + 6.3b-i 242.3 f 6.0dJ 50.5 f 1.3”k 43.8 f 0.8hJ 
Differences between pairs of values with the same superscript letters (in the same columns in the Table) are as follows: a,c.dP < 
0.001; bP < 0.01; e*g*h.kP < 0.0001; ‘P < 0.0002; f.iP NS. 
was prevented by 30% (P c 0.0002) in ARI- 
treated animals (Table l), which still showed a sig- 
nificant (P < 0.0001) 29% slowing of NCV com- 
pared with control animals (Table 1). 
3.3. Biochemical analyses 
Biochemical analyses were performed on sciatic 
nerves of S-month animals only. Galactosemia or 
ARI-treatment had no effects on nerve glucose, 
sorbitol, or fructose levels. Galacosemia resulted 
in elevated nerve galactose levels, which were not 
affected by ARI-treatment (Table 2). As expected, 
galactitol levels were markedly increased in galac- 
tosemic animals and were reduced by 97% with 
ARI-treatment (Table 2). Nerve myo-inositol lev- 
els were reduced by approximately 50% (P < 0.05) 
in untreated galactosemic rats, a reduction which 
was completely prevented by ARI-treatment (P < 
0.01) (Table 2). 
3.4. Morphologic and morphometric changes 
Qualitative findings 
Ultrastructural examinations of 4-month galac- 
tosemic rats demonstrated the presence of endo- 
neurial edema, axonal glycogenosomes, myelin 
splitting and dystrophic Schwann cells. These 
changes with the exception of glycogenosomes 
appeared less frequently in 4-month ARI-treated 
galactosemic animals. Subperineurial and peri- 
vascular endoneurial edema appeared less promi- 
nent in 8-month galactosemic animals than in 
animals galactosemic for 4 months (Fig. la, b), 
and seemed to be prevented by 8 months of ARI- 
treatment (Fig. lc). At 8 months axonal atrophy, 
myelin splitting and dystrophic Schwann cells con- 
taining densely packed cytoplasmic filaments 
and/or large amounts of glycogen granules were 
commonly observed. These changes, with the 
exception of axonal glycogenosomes, appeared 
Table 2 
The effect of galactosemia and ARI-treatment on nerve carbohydrate and polyol levels in I-month animals 
Glucose Sorbitol 
(nmol/mg (nmol/mg 













Control (n = 5) 5.3 l 0.9 0.5 l 0.1 2.8 zt 0.6 0” 0” 10.3 f l.6b 
Galactose (n = 5) 5.0 * 0.8 0 1.4 f 0.1 28.3 zt 6.0 72.1 f 8.3”,’ 4.7 f 0.4b.d 
Galactose + AR1 7.2 f 2.1 0.4 l 0.1 0.9 f 0.2 18.0 f 5.2 2.2 * 0.3c 10.7 ziz 0.8d 
(n = 5) 
Differences between pairs of values with the same superscript letters (in the same columns in the Table) are as follows: a.bP < 0.05; 
CqdP < 0.01. 
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Fig. I. Cross-sections of the sural nerve in (a) 4-month galac- 
tosemic rat, (b) 8-month galactosemic rat, and (c) 8-month 
ARI-treated galactosemic rat. Note in (a) modest endoneurial 
edema and fibers showing myelin splitting (arrows), in (b) mild 
residual edema and persistent myelin splitting (arrows), and in 
(c) no noticeable edema, an increase in small presumably 
regenerating fibers (arrows), and persistent axonal atrophy. 
Magnification, x 90. 
less frequent in 8-month ARI-treated galactosemic 
rats (Fig. 2), whereas the number of remyelinated 
and regenerated fibers, characterized by propor- 
tionately thin myelin sheaths and excessive base- 
ment membranes was increased (Fig. 3). 
Quantitative changes 
Axonal abnormalities. Myelinated fiber size and 
density were not affected by 4 months of galac- 
tosemia. In contrast, simultaneous ARI-treatment 
resulted in a significant (P < 0.05) increase in fiber 
density associated with a significant (P c 0.05) 
decrease in myelinated fiber size compared with 
untreated galactosemic rats (Table 3). Similar 
changes were also demonstrated in 8-month ARI- 
treated galactosemic animals (Table 3). The sever- 
ity of axonal atrophy reflected by diminished fiber 
size in galactosemic rats (14%) did not reach 
statistical significance (Table 3), whereas the ex- 
tent of axonal atrophy reflected by the more sensi- 
tive technique [28] of assessing the frequency of 
teased fibers exhibiting excessive myelin wrinkling 
was increased more than 4-fold (P < 0.002) in 
galactosemic rats than in control rats (Table 3). 
This effect of galactosemia was not significantly 
(17%; NS) prevented by ARI-treatment (Table 3). 
The CV of fiber density between frames indicating 
focal fiber loss was not altered by galactosemia or 
ARI-treatment in 4- or 8-month rats (data not 
shown). Nerve fiber regeneration was not signili- 
cantly increased in 8-month galactosemic rats, 
whereas simultaneous ARI-treatment resulted in a 
4-fold (P < 0.0001) increase in regenerated 
myelinated fibers, compared with untreated galac- 
tosemic rats (Table 3). 
Nodal changes. The preventive effect of ARI- 
treatment on structural changes in 8-month galac- 
tosemic animals was reflected in a 50% (P < 
0.0001) preservation of structurally normal fibers 
(Fig. 4a; Table 4). Eight months of galactosemia 
had a profound effect on nodal structural changes: 
paranodal swelling (Fig. 4b, c) was increased more 
than 5-fold (P < 0.0001); axo-glial dysjunction 
was increased by more than 300% (P c 0.0001) 
(Fig. 5), and the frequency of paranodal 
demyelination (Fig. 4c, d) and intercalated inter- 
nodes (Fig. 4e) was increased more than 5- (P c 
0.0002) and 1Cfold (P < O.OOOl), respectively 
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Fig. 2. Electronmicrograph from an 8-month ARI-treated galactosemic rat showing residual axonal atrophy, axonal glycogenosomes 
(arrows), glycogen accumulation in the Schwann cell cytoplasm (asterisk), and relative absence of endoneurial edema. Magnification, 
x 2350. 
(Table 4). These sequential nodal changes 
characteristic of diabetic neuropathy were all 
prevented by ARI-treatment, except for axoglial 
dysjunction that was significant reduced (P < 
0.001) but not completely prevented by ARI- 
treatment (Table 4). 
4. Discussion 
Both chronic galactosemia and hyperglycemia 
activates the polyol pathway with accumulation of 
galactitol and sorbitol, respectively, both of which 
have a compensatory effect on other organic 
osmolites, particularly myoinositol which becomes 
depleted in both conditions [ 1,3,9,30,3 11. Since 
myoinositol depletion has been invoked as an im- 
portant early pathogenetic mechanism in diabetic 
neuropathy [1,4,9,32], it has been assumed that 
chronic galactosemia may serve as a useful model 
for the study of consequent polyol-pathway re- 
lated metabolic, functional and structural abnor- 
malities occurring in diabetic neuropathy [ 1,32, 
331, and to test their responsiveness to treatment 
with ARIs. 
In the present study we have confirmed earlier 
data demonstrating myoinositol depletion conse- 
quent to galactitol accumulation in peripheral 
nerve, and its correction following ARI-treatment 
[30,33,34]. The treatment with an AR1 was accom- 
panied by a complete prevention of the nerve con- 
duction slowing observed in 4-month galactosemic 
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Fig. 3. Thinly myelinated fiber in 8-month ARI-treated galactosemic rat showing redundant basement membrane 
chat ,acteristic of regenerated fibers. Magnification, I1 500. 
(arro ‘WS) 
Table 3 
The effect of galactosemia and ARI-treatment on myelinated liber density and size and axon/myelin ratio in 4- and I-month rats and 
the effect of 8 months of galactosemia and simultaneous ARI-treatment on excessively wrinkled myelinated fibers and myelinated 
fiber regeneration 
Axonal changes 









Control (n = 5) 
Galactose (n = 5) 
Galactose + AR1 
(?I = 5) 
I4 626 f 172”qb 32.8 zt 0.8b.C 0.75 * 0.02d.e 
I3 500 zt 725”,’ 31.0 zt 2.4b.s 0.64 f 0.04d.h 
15401 f 739f.b 26.9 f 1.6c,s 0.74 f 0.06e,h 
8 Months 
Control (n = 5) 
Galactose (n = 5) 
Galactose + ARI 
(n = 5) 
I3 937 f 252’5 
I2 090 zt 328’*’ 
14917 rt 265J.l 
39.8 f 2.0k*’ 
34.2 f 2.9k*’ 
27.6 f l.l’,’ 
0.66 f O.O5rn,” 
0.62 + 0.03m,U 
0.68 f 0.04”,” 
2.27 zt 0.65O+ 
10.25 f I .69”,” 
8.90 f 1.55p.v 
0.34 f 0.21s.’ 
2.94 f 0.67s.” 
13.92 f l.14’,w 
Differences between pairs of values with the same superscript letters (in the same columns in the Table) are as follows: 
a.b.d.e.h.ij.k.m.n.q.u.vp NS; c.sp < 0.01; f@P < 0.05; ‘P < 0.001; OP < 0.002; PP < 0.02; r.wP < 0.0001. 
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Fig. 4. Sequence of nodal and paranodal changes in teased fibers from 8-month galactosemic rats. (a) normal nodes of Ranvier 
(arrows); (b) paranodal swelling; (c) paranodal demyelination with markedly swollen paranodal axon; (d) paranodal demyelination 
without axonal swelling; and (e) intercalated (remyelinated) internode. Magnification, X 1200. 
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Table 4 
The effect of 8 months of galactosemia and ARI-treatment on normality and structural nodal changes 
Nodal changes 
Normal (%) Paranodal Axo-glial 





Control (n = 5) 92.3 f 0.6”b, 2.83 f 0.55’ 13.3 f 0.5d.e 1.06 zt 0.3’s 0.54 l 0.37hJ 
Galactose (n = 5) 55.4 f 1.6”J 15.5 f 1.5W 44.8 f 0.9d.’ 6.04 f 1.03f.m 7.99 f l.06h~” 
Galactose + AR1 74.3 + 2.3bJ 1.37 f 0.27k 22.1 l 2.1rJ 0.47 l 0.31sm 0.62 + 0.29’,” 
(n = 5) 
Differences between pairs of values with the same superscript letters (in the same columns in the Table) are as follows: a.c.d.hJ.k.m.“P 
0.0001: b.‘P < 0.001; eP < 0.005; ‘P < 0.0002; g,‘P NS. 
animals, an effect that was only partially sustained 
in &month ARI-treated galactosemic rats. 
In diabetic neuropathy, the acute nerve conduc- 
tion slowing has been closely related to the per- 
turbations of myoinositol depletion affecting 
phosphoinositide metabolism and Na+K+- 
ATPase activity [1,32]. Since Na+K+-ATPase ac- 
tivity in the galactosemic nerve is increased [7,13] 
Fig. 5. Electronmicrographs of the paranodal regions; (a) in a normal control rat showing axoglial junctions between myelin loops 
and the axolemma (arrows; magnification x 20 750). and (b) in an I-month galactosemic non-treated rat showing loss of axo-glial 
junctions (arrows), and myelin loops showing intact junctions (arrowheads; magnification, x 22 600. 
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rather than decreased as is characteristic of 
diabetic nerve [35], the mechanism underlying the 
acute nerve conduction slowing in galactosemia 
may be different. Recently both metabolic and 
vascular factors have been implicated in the acute 
nerve conduction slowing in diabetes [36-381. The 
suggested vascular mechanism involves inhibition 
of nitric oxide synthase [39] with an effect on nitric 
oxide and consequent vasoconstriction rendering 
the nerve hypoxic [40]. Since NADPH is an 
obligate co-factor for both aldose reductase (re- 
sponsible for the conversion of galactose to galac- 
titol) and nitric oxide synthase [41], activation of 
aldose reductase by galactosemia may limit nitric 
oxide synthesis by co-factor competition produc- 
ing vasoconstriction, ischemia, and nerve conduc- 
tion slowing, without necessarily invoking a defect 
in Na+K+-ATPase. In addition, mechanical fac- 
tors such as increased endoneurial pressure in the 
galactosemic nerve may further compromise endo- 
neurial blood flow [11,33]. Simultaneous treat- 
ment with an ARI, which inhibits the aldose 
reductase activity as well as the formation of endo- 
neurial edema (331, would therefore eliminate the 
competition for NADPH, increase blood flow and 
restore the nerve conduction defect in the early 
stage of galactosemic neuropathy, before the axon 
has become structurally compromised. This ap- 
pears to be the case in the present 4-month galac- 
tosemic animals, since mean fiber size was not 
affected. 
In contrast at 8 months of galactosemia, ARI- 
treatment had only a partial effect on NCV, which 
was associated with a partial preventive effect on 
axonal atrophy as indicated by the frequency of 
myelinated fibers exhibiting excessive myelin 
wrinkling. It is possible that the failure of the ARI- 
treatment to prevent the nerve conduction defect 
at this point may, at least in part, be due to the 
development of resistant axonal atrophy. These 
findings are in contrast to those demonstrated in 
the spontaneously diabetic rat, in which long-term 
ARI-treatment is associated with a protection of 
axonal atrophy, suggesting that the mechanisms 
responsible for the progressive axonal atrophy in 
the two models are not the same [23]. 
Axonal size is dependent on the integrity of 
structural protein polymerization, which under 
hyperglycemic conditions is affected by non- 
enzymatic glycation by monosaccharides [42]. 
Since nerve galactose levels were not affected by 
AR1 treatment, and galactose being a more potent 
protein glycator than glucose 19,431, it may be re- 
sponsible for the resistant axonal atrophy. In con- 
trast, AR&treatment of diabetic nerve prevents, 
besides sorbitol accumulation, the excessive 
production of fructose, which is an even more po- 
tent glycator than glucose and galactose [9,44]. 
Therefore, by implicating non-enzymatic glycation 
in axonal atrophy, this reasoning could explain the 
more favorable effect of ARIs on axonal atrophy 
in diabetic neuropathy. 
Hence, the present study has confirmed many 
of the earlier reported neuropathic Iindings in 
chronic galactosemia [5,12,29,30]. In addition, in 
galactosemic rats we have identified a series of 
nodal changes which are characteristic of experi- 
mental murine models of diabetic neuropathy 
[14,16,22,23], and human diabetic neuropathy 
[15,24,26,28]. The emergence of these changes in 
galactosemic neuropathy is not totally surprising, 
since in diabetic neuropathy they have been closely 
linked to the polyol-pathway, which appears to be 
topographically and preferentially located to the 
paranodal Schwann cell [45,46]. In diabetic 
neuropathy we have previously demonstrated that 
the early nodal swelling is associated with a 5-fold 
increase in intraaxonal Na+ [47], and suggested 
that this defect is related to impaired activity of 
Na+/K+-ATPase [32]. It is difftcult, however, to 
reconcile a similar mechanism in galactosemic 
neuropathy, since Na+/K+-ATPase activity is in- 
creased in this condition [1,21,32]. However, the 
topographic distribution of Na+/K+-ATPase in 
galactosemic peripheral nerve is unknown. It has 
been suggested that the increased Na+/K+- 
ATPase activity in galactosemia is compensatory 
to increased subperineurial and perivascular Na+- 
rich endoneurial edema [7,33]. The total neural 
increase in Na+/K+-ATPase activity may 
therefore be accounted for by increased activity 
located to the perineurium and the endoneurial 
vasculature rather than to the nodal apparatus. 
However, these possible explanations for divergent 
activities and localizations of Na+/K+-ATPase in 
galactosemic versus diabetic neuropathy will need 
further exploration. The subsequent structural 
nodal changes have been more directly related to 
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the perturbed myoinositol metabolism [48] which 
is common to both galactosemic and diabetic 
neuropathy. Axo-glial junctions constituting the 
paranodal ion-channel barrier are believed to rely 
on inositol dependent cell adhesive molecules for 
their integrity [49], and their disruption is prob- 
ably the initiating event heralding paranodal 
demyelination and the subsequent reparative 
nodal remyelination and formation of intercalated 
internodes [22,23]. 
In the present study axo-glial dysjunction was 
not fully prevented by AR1 treatment, and the 
residual defect in the paranodal ion-channel 
barrier, may in part explain the incomplete preven- 
tion of the nerve conduction defect, since in both 
experimental and human diabetic neuropathy the 
paranodal barrier defect is closely associated with 
the nerve conduction slowing [23,26]. 
Nerve fiber regeneration is impaired in both 
galactosemic neuropathy [ 121 and diabetic neuro- 
pathy [23,24]. In the present study, galactosemic 
animals exhibited no significant increase in the fre- 
quency of regenerating fibers, despite ongoing 
nerve fiber degeneration. AR&treated galacto- 
semic rats demonstrated an increased frequency of 
regenerating fibers, which is similar to the 
regenerative response found in both experimental 
and human diabetic neuropathy following ARI- 
treatment [23,24,26]. The mechanisms responsible 
for this subdued regenerative capacity are not 
completely understood, although impaired expres- 
sion of neurotrophic factors have been suggested 
in diabetic neuropathy [50,51]. Possible 
mechanisms are presently being investigated in 
several laboratories, including our own. 
In summary, the present study has confirmed 
previous findings in chronic galactosemic 
neuropathy. Furthermore, it has identified a series 
of ARI-responsive nodal changes characteristic of 
diabetic neuropathy. We conclude that chronic 
galactosemia in the rat may be a useful model for 
the study of specific abnormalities occurring in 
diabetic neuropathy and their responses to inhibi- 
tion of the polyol pathway. 
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